: Hemophilia A is a bleeding disorder caused by a deficiency of clotting factor VIII. Approximately 20% of the patients develop inhibitors in response to replacement therapy with factor VIII concentrates. Once inhibitors develop, hemostatic management becomes very difficult because replacement therapy is generally ineffective. We report a case of persistent post-extraction bleeding in a hemophilia A patient with high responding inhibitors. A 24-year-old man was referred to our department for dental treatment. He had a history level of treatment with factor VIII inhibitor (21 Bethesda units/ml) . Clinical and radiological examinations revealed that the upper right second molar and left second premolar required dental extraction. We consulted his hematologist and performed dental extraction during factor VIII-bypassing therapy with recombinant activated factor VIIa (rFVIIa) according to the hemostatic treatment guidelines for inhibitors in patients with congenital hemophilia, 2013 revised edition. However, the hemorrhagic oozing out of the extraction sockets repeatedly occurred despite additional curettage of the sockets and application of a mouth splint. Then, we changed the bypass agent to activated prothrombin complex concentrates (aPCC) , and successful hemostasis was achieved without serious complications. On the 18th postoperative day, complete epithelial closure of the sockets was observed.
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: hemophilia A inhibitor (血友病 A インヒビター) ， recombinant activated factor VII : rFVIIa (遺伝子組換え 活性型凝固第 VII 因子製剤) ， activated prothrombin complex concentrates : aPCC (活性型プロトロンビン 複合体製剤) ， hemostatic management (止血管理) ， tooth extraction (抜歯)

